Candel Therapeutics entered into a Second Amended and Restated Open Market Sale Agreement with Jefferies LLC to establish a new at-the-market (ATM) equity facility. The agreement allows the company to sell up to $50 million of common stock from time to time, in addition to the $50 million previously sold under a prior 2025 agreement.
Candel Therapeutics reported a significant increase in cash and cash equivalents to $203.1 million as of September 30, 2026, primarily driven by $142.6 million in net proceeds from public and at-the-market equity offerings. However, the company experienced a substantial increase in net loss to $69.6 million for the first nine months of 2026, compared to $8.7 million in the prior year, largely due to higher R&D spending and a negative swing in the fair value of warrant liabilities.
Candel Therapeutics reported third quarter 2026 financial results, ending the period with $203.1 million in cash which is expected to fund operations into Q2 2028. The company updated its regulatory timeline, now planning to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in mid-2027 following assay refinement. Recent clinical progress included three poster presentations at the SITC 41st Annual Meeting showcasing data across its prostate, lung, and glioma programs.
Term
Q3 2026
“During the quarter we continued to execute well and make significant progress across the business, as we build the foundation to potentially become a commercial-stage biopharma company.”
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO
“On the clinical side, we were honored to have had three posters accepted for presentation at SITC, featuring data on aglatimagene in localized prostate cancer and non-small cell lung cancer, and linoserpaturev in recurrent high-grade glioma. Together, the new biomarker data provide mechanistic support for the systemic effect and long-term clinical outcomes observed in our phase 3 trial of aglatimagene in patients with intermediate- to high-risk localized prostate cancer.”
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO